Complete Filing Data
Neumora Therapeutics, Inc. reported Stockholders Equity of $103.87 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Neumora Therapeutics, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Income * | -$236.9M | -$243.8M | -$235.9M | -$130.9M |
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | -$62.0K | $138.0K | $698.0K | -$774.0K |
| Research And Development Expense | $176.1M | $200.9M | $142.7M | $91.7M |
| Other Nonoperating Income Expense | -$767.0K | -$78.0K | -$170.0K | $405.0K |
| Operating Income Loss | -$241.2M | -$263.5M | -$252.1M | -$135.9M |
| Operating Expenses | $241.2M | $263.5M | $252.1M | $135.9M |
| Nonoperating Income Expense | $4.4M | $19.9M | $16.4M | $5.0M |
| General And Administrative Expense | $60.1M | $62.5M | $45.5M | $31.1M |
| Comprehensive Income Net Of Tax | -$237.0M | -$243.6M | -$235.2M | -$131.7M |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$236.8M | -$243.6M | -$235.7M | -$130.9M |
| Interest Income Expense Nonoperating Net | $19.9M | $16.6M | $4.6M | |
| Income Tax Expense Benefit | $130.0K | $178.0K | $268.0K | |
| Acquired In Process Research And Development | $5.0M | $0.00 | $63.9M | $13.0M |
| Income Taxes Paid Net | $323.0K | $473.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$56.8M | -$52.7M | -$68.0M | -$72.5M | -$58.7M | -$53.7M | -$53.0M | -$38.5M | -$35.6M | -$29.3M | -$30.4M | -$43.0M |
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | $24.0K | -$12.0K | -$65.0K | $292.0K | -$39.0K | -$72.0K | $137.0K | -$150.0K | $476.0K | -$284.0K | -$692.0K | -$178.0K |
| Research And Development Expense | $40.5M | $38.7M | $52.2M | $60.6M | $48.6M | $45.8M | $41.6M | $32.8M | $29.5M | $22.5M | ||
| Other Nonoperating Income Expense | $7.0K | -$480.0K | -$25.0K | -$57.0K | -$24.0K | -$12.0K | -$1.0K | -$39.0K | -$26.0K | -$148.0K | ||
| Operating Income Loss | -$57.7M | -$54.0M | -$70.9M | -$76.6M | -$63.8M | -$60.1M | -$56.9M | -$42.1M | -$39.2M | -$30.6M | ||
| Operating Expenses | $57.7M | $54.0M | $70.9M | $76.6M | $63.8M | $60.1M | $56.9M | $42.1M | $39.2M | $30.6M | ||
| Nonoperating Income Expense | $945.0K | $1.3M | $3.0M | $4.2M | $5.2M | $6.4M | $3.8M | $3.5M | $3.5M | $1.3M | ||
| General And Administrative Expense | $12.2M | $15.3M | $18.8M | $16.0M | $15.2M | $14.3M | $15.3M | $9.3M | $9.7M | $8.1M | ||
| Comprehensive Income Net Of Tax | -$56.7M | -$52.7M | -$68.1M | -$72.3M | -$58.7M | -$53.8M | -$52.9M | -$38.7M | -$35.1M | -$29.6M | ||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$56.8M | -$52.7M | -$67.9M | -$72.5M | -$58.6M | -$53.7M | -$53.0M | -$38.5M | ||||
| Interest Income Expense Nonoperating Net | $1.8M | $3.1M | $4.2M | $5.3M | $6.4M | $3.8M | $3.6M | $3.6M | ||||
| Income Tax Expense Benefit | $0.00 | $25.0K | $105.0K | $53.0K | $125.0K | |||||||
| Acquired In Process Research And Development | $5.0M | $0.00 | ||||||||||
| Income Taxes Paid Net |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Stockholders Equity | $103.9M | $287.1M | $469.1M | -$446.9M | -$325.2M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $182.5M | $143.4M | $375.3M | $242.2M | $409.4M |
| Cash And Cash Equivalents At Carrying Value | $182.5M | $142.1M | $374.0M | $240.9M | |
| Restricted Cash And Cash Equivalents | $182.5M | $143.4M | $375.3M | $242.2M | |
| Restricted Cash | $0.00 | $1.2M | $1.2M | $1.3M | |
| Noncash Operating Lease Expense | $1.9M | $3.3M | $3.4M | $2.1M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $39.2M | -$231.9M | $133.0M | -$167.2M | |
| Retained Earnings Accumulated Deficit | -$1.18B | -$947.2M | -$703.4M | -$467.5M | |
| Property Plant And Equipment Net | $40.0K | $1.1M | $1.8M | $2.4M | |
| Prepaid Expense And Other Assets Current | $8.0M | $5.3M | $24.3M | $16.0M | |
| Operating Lease Right Of Use Asset | $417.0K | $1.8M | $5.1M | $8.2M | |
| Operating Lease Liability Current | $284.0K | $1.9M | $3.4M | $3.4M | |
| Liabilities Current | $32.5M | $29.9M | $25.1M | $23.7M | |
| Liabilities And Stockholders Equity | $191.0M | $317.0M | $496.2M | $426.2M | |
| Liabilities | $87.2M | $29.9M | $27.1M | $29.4M | |
| Common Stock Value | $17.0K | $16.0K | $16.0K | $3.0K | |
| Assets Current | $190.5M | $314.1M | $478.3M | $388.0M | |
| Assets | $191.0M | $317.0M | $496.2M | $426.2M | |
| Additional Paid In Capital Common Stock | $1.29B | $1.23B | $1.17B | $21.4M | |
| Accrued Liabilities Current | $28.8M | $24.6M | $21.3M | $11.5M | |
| Accounts Payable Current | $3.4M | $3.3M | $337.0K | $7.1M | |
| Marketable Securities Current | $165.4M | $79.9M | $130.9M | ||
| Early Exercise Liability Current Portion | $133.0K | $139.0K | $1.6M | ||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $62.0K | -$76.0K | -$774.0K | ||
| Early Exercise Liability Net Of Current Portion | $22.0K | $155.0K | $628.0K | ||
| Operating Lease Liability Noncurrent | $193.0K | $1.9M | $5.1M | ||
| Restricted Cash Noncurrent | $0.00 | $1.2M | $1.2M | ||
| Restricted Cash Current | $1.2M | $50.0K | |||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | $532.0K | $0.00 | $192.0K | $8.9M | |
| Stock Issued During Period Value Vesting Of Common Stock Subject To Repurchase | $155.0K | $140.0K | |||
| Marketable Securities Noncurrent | $9.8M | $23.5M | |||
| Other Assets Noncurrent | $53.0K | $2.9M | |||
| Operating Lease Liability In Connection With New Lease Agreement | $505.0K | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $132.2M | $182.9M | $228.4M | $320.7M | $381.3M | $424.5M | $512.7M | -$513.5M | -$477.9M | -$422.0M | -$394.7M | -$366.0M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $129.1M | $124.5M | $128.1M | $276.9M | $151.9M | $184.1M | $413.5M | $205.4M | $212.1M | $253.8M | |||
| Cash And Cash Equivalents At Carrying Value | $129.1M | $124.5M | $126.9M | $275.7M | $150.7M | $182.9M | $412.3M | $204.2M | $210.9M | $252.5M | |||
| Restricted Cash And Cash Equivalents | $129.1M | $124.5M | $128.1M | $276.9M | $151.9M | $184.1M | $413.5M | $205.4M | $212.1M | $253.8M | |||
| Restricted Cash | $0.00 | $0.00 | $1.2M | $1.2M | $1.2M | $1.2M | $1.2M | $1.2M | $1.2M | $1.3M | |||
| Noncash Operating Lease Expense | $877.0K | $791.0K | $799.0K | ||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$15.3M | -$191.1M | -$30.1M | ||||||||||
| Retained Earnings Accumulated Deficit | -$1.12B | -$1.07B | -$1.02B | -$888.4M | -$815.9M | -$757.2M | -$594.7M | ||||||
| Property Plant And Equipment Net | $80.0K | $87.0K | $982.0K | $1.3M | $1.5M | $1.6M | $1.9M | ||||||
| Prepaid Expense And Other Assets Current | $5.6M | $5.3M | $4.3M | $6.1M | $26.7M | $20.1M | $16.2M | ||||||
| Operating Lease Right Of Use Asset | $474.0K | $531.0K | $900.0K | $2.6M | $3.5M | $4.3M | $6.0M | ||||||
| Operating Lease Liability Current | $256.0K | $171.0K | $938.0K | $2.7M | $3.6M | $3.5M | $3.4M | ||||||
| Liabilities Current | $25.8M | $21.2M | $28.4M | $31.7M | $23.1M | $24.6M | $29.1M | ||||||
| Liabilities And Stockholders Equity | $177.8M | $223.8M | $256.7M | $352.5M | $404.5M | $450.2M | $544.7M | ||||||
| Liabilities | $45.7M | $40.9M | $28.4M | $31.8M | $23.2M | $25.7M | $32.1M | ||||||
| Common Stock Value | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $15.0K | ||||||
| Assets Current | $177.1M | $222.9M | $254.9M | $348.6M | $398.3M | $442.8M | $525.7M | ||||||
| Assets | $177.8M | $223.8M | $256.7M | $352.5M | $404.5M | $450.2M | $544.7M | ||||||
| Additional Paid In Capital Common Stock | $1.26B | $1.25B | $1.24B | $1.21B | $1.20B | $1.18B | $1.11B | ||||||
| Accrued Liabilities Current | $25.0M | $20.3M | $26.3M | $22.8M | $18.3M | $19.5M | $23.3M | ||||||
| Accounts Payable Current | $549.0K | $644.0K | $1.1M | $6.1M | $1.1M | $1.5M | $2.2M | ||||||
| Marketable Securities Current | $42.5M | $93.1M | $122.5M | $65.6M | $221.0M | $239.8M | $97.3M | ||||||
| Early Exercise Liability Current Portion | $55.0K | $88.0K | $122.0K | $133.0K | $133.0K | $133.0K | $149.0K | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $9.0K | -$15.0K | -$3.0K | $105.0K | -$187.0K | -$148.0K | -$311.0K | ||||||
| Early Exercise Liability Net Of Current Portion | $0.00 | $0.00 | $55.0K | $89.0K | $122.0K | $188.0K | |||||||
| Operating Lease Liability Noncurrent | $267.0K | $339.0K | $0.00 | $938.0K | $2.7M | ||||||||
| Restricted Cash Noncurrent | $1.2M | $1.2M | $1.2M | ||||||||||
| Restricted Cash Current | $0.00 | $0.00 | $1.2M | $1.2M | |||||||||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | |||||||||||||
| Stock Issued During Period Value Vesting Of Common Stock Subject To Repurchase | $33.0K | $34.0K | $33.0K | ||||||||||
| Marketable Securities Noncurrent | $302.0K | $9.9M | |||||||||||
| Other Assets Noncurrent | $197.0K | $298.0K | $0.00 | ||||||||||
| Operating Lease Liability In Connection With New Lease Agreement |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition | $29.9M | $40.0M | $17.2M | $8.3M |
| Share Based Compensation | $29.9M | $40.0M | $17.2M | $8.3M |
| Proceeds From Stock Options Exercised | $0.00 | $7.5M | $2.9M | $2.7M |
| Payments To Acquire Marketable Securities | $82.9M | $312.2M | $109.1M | $226.4M |
| Net Cash Provided By Used In Operating Activities | -$206.4M | -$182.9M | -$163.3M | -$114.9M |
| Net Cash Provided By Used In Investing Activities | $168.5M | -$70.6M | $64.4M | -$168.0M |
| Net Cash Provided By Used In Financing Activities | $77.1M | $21.6M | $231.9M | $115.7M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $2.8M | -$15.9M | $11.4M | $3.6M |
| Increase Decrease In Operating Lease Liability | -$1.9M | -$3.4M | -$3.4M | -$1.8M |
| Increase Decrease In Accrued Liabilities | $4.2M | $7.2M | $6.5M | -$1.6M |
| Increase Decrease In Accounts Payable | $71.0K | $2.9M | -$581.0K | -$1.2M |
| Depreciation Depletion And Amortization | $208.0K | $631.0K | $668.0K | $594.0K |
| Payments To Acquire In Process Research And Development | $0.00 | $775.0K | $4.6M | $13.0M |
| Proceeds From Maturities Of Marketable Securities | $251.2M | $242.4M | $178.2M | $71.9M |
| Payments To Acquire Property Plant And Equipment | $117.0K | $511.0K | ||
| Payments Of Stock Issuance Costs | $3.8M | $744.0K | ||
| Increase Decrease In Other Operating Capital Net | $53.0K | $0.00 | -$1.4M | |
| Proceeds From Stock Plans | $275.0K | $427.0K | ||
| Proceeds From Sale Of Property Plant And Equipment | $218.0K | $0.00 | ||
| Proceeds From Sale And Maturity Of Marketable Securities | $178.2M | $71.9M | ||
| Proceeds From Long Term Lines Of Credit | $57.2M | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition | $6.0M | $7.2M | $9.3M | $9.9M | $12.8M | $7.4M | $6.5M | $2.5M | $2.2M | $2.1M | $1.8M | $1.7M |
| Share Based Compensation | $9.3M | $7.4M | $2.2M | |||||||||
| Proceeds From Stock Options Exercised | $0.00 | $1.8M | $602.0K | |||||||||
| Payments To Acquire Marketable Securities | $44.4M | $185.8M | $41.5M | |||||||||
| Net Cash Provided By Used In Operating Activities | -$59.4M | -$43.0M | -$33.0M | |||||||||
| Net Cash Provided By Used In Investing Activities | $44.2M | -$150.0M | $2.8M | |||||||||
| Net Cash Provided By Used In Financing Activities | $0.00 | $1.8M | $101.0K | |||||||||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$966.0K | -$7.4M | -$7.9M | |||||||||
| Increase Decrease In Operating Lease Liability | -$915.0K | -$802.0K | -$801.0K | |||||||||
| Increase Decrease In Accrued Liabilities | $1.7M | -$4.1M | -$736.0K | |||||||||
| Increase Decrease In Accounts Payable | -$2.3M | $1.2M | -$6.0M | |||||||||
| Depreciation Depletion And Amortization | $157.0K | $158.0K | $158.0K | |||||||||
| Payments To Acquire In Process Research And Development | $0.00 | $775.0K | ||||||||||
| Proceeds From Maturities Of Marketable Securities | $88.5M | $36.6M | ||||||||||
| Payments To Acquire Property Plant And Equipment | $36.0K | |||||||||||
| Payments Of Stock Issuance Costs | $10.0K | |||||||||||
| Increase Decrease In Other Operating Capital Net | ||||||||||||
| Proceeds From Stock Plans | ||||||||||||
| Proceeds From Sale Of Property Plant And Equipment | ||||||||||||
| Proceeds From Sale And Maturity Of Marketable Securities | $36.6M | $44.3M | ||||||||||
| Proceeds From Long Term Lines Of Credit |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 163.4M | 159.4M | 65.0M | 27.2M |
| Weighted Average Number Of Diluted Shares Outstanding | 163.4M | 159.4M | 65.0M | 27.2M |
| Earnings Per Share Diluted | $-1.45 | $-1.53 | $-3.63 | $-4.81 |
| Earnings Per Share Basic | $-1.45 | $-1.53 | $-3.63 | $-4.81 |
| Preferred Stock Shares Authorized | 50.0M | 50.0M | 50.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 161.8M | 161.7M | 161.5M | 159.6M | 159.0M | 157.9M | 46.7M | 30.1M | 29.3M | 27.6M |
| Weighted Average Number Of Diluted Shares Outstanding | 161.8M | 161.7M | 161.5M | 159.6M | 159.0M | 157.9M | 46.7M | 30.1M | 29.3M | 27.6M |
| Earnings Per Share Diluted | $-0.35 | $-0.33 | $-0.42 | $-0.45 | $-0.37 | $-0.34 | $-1.14 | $-1.28 | $-1.22 | $-1.06 |
| Earnings Per Share Basic | $-0.35 | $-0.33 | $-0.42 | $-0.45 | $-0.37 | $-0.34 | $-1.14 | $-1.28 | $-1.22 | $-1.06 |
| Preferred Stock Shares Authorized |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Stock Issued During Period Value Stock Options Exercised | $275.0K | $7.5M | $2.9M | $612.0K |
| Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | $1.5M | $1.1M | ||
| Investment Income Amortization Of Discount | $2.9M | $5.7M | $3.7M | $708.0K |
| Other Noncash Income Expense | -$23.0K | -$120.0K | -$228.0K | |
| Repurchase Of Unvested Early Exercised Shares | 491.0K | |||
| Investment Income Interest | $8.3M | $19.9M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Issued During Period Value Stock Options Exercised | $59.0K | $1.8M | $2.7M | $1.8M | $1.5M | $404.0K | $602.0K | $148.0K | $258.0K | $164.0K | ||
| Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | $33.0K | $34.0K | $41.0K | $47.0K | $125.0K | $1.3M | $86.0K | $340.0K | $606.0K | |||
| Investment Income Amortization Of Discount | $1.3M | $1.1M | $892.0K | |||||||||
| Other Noncash Income Expense | -$15.0K | |||||||||||
| Repurchase Of Unvested Early Exercised Shares | 491.0K | |||||||||||
| Investment Income Interest | $1.7M | $4.2M |
Most recent annual filing with the SEC: March 30, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.